Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M (2012)


Publication Type: Journal article

Publication year: 2012

Journal

Book Volume: 131

Pages Range: E10-E20

Journal Issue: 2

DOI: 10.1002/ijc.26464

Abstract

Receptor-targeted therapies have become standard in the treatment of various lymphomas. In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell lymphoma cells is a potential therapeutic target. We have used two BCR epitope mimicking peptides binding to the Burkitt's lymphoma cell lines CA46 and SUP-B8. We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon peptide receptor binding. Toxicity experiments in vitro via cross-linking of the BCR with tetramerized epitope mimics lead to apoptosis in both cell lines but was far more effective in SUP-B8 cells. We established a SUP-B8-based disseminated Burkitt's lymphoma model in NOD/SCID mice. Treatment of tumor-bearing mice with tetramerized epitope mimics had significant anti-tumor effects in vivo. We conclude that peptide-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive lymphoma. Copyright © 2011 UICC.

Involved external institutions

How to cite

APA:

Wehr, C., Müller, F., Schüler, J., Tomann, T., Nitschke, C., Seismann, H.,... Trepel, M. (2012). Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. International Journal of Cancer, 131(2), E10-E20. https://doi.org/10.1002/ijc.26464

MLA:

Wehr, Claudia, et al. "Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model." International Journal of Cancer 131.2 (2012): E10-E20.

BibTeX: Download